Niall J Lennon, Ph.D. is the Senior Director of Translational Genomics at the Broad Institute of MIT and Harvard, where he is also an Institute Scientist. He is also the Chief Scientific Officer and Chair of the Board of Managers of Broad’s clinical testing laboratory. Dr. Lennon is also an Associate Director of the Gerstner Center for Cancer Diagnostics. He oversees the development, implementation, and validation of disruptive technologies to serve basic research, clinical research, and clinical diagnostics.
Dr. Lennon has been with the Broad since 2005 and has contributed to the development of applications for every major massively parallel sequencing platform across a range of fields. In 2013, Dr. Lennon built a CLIA/CAP licensed clinical laboratory at the Broad to facilitate return of results to patients and to support clinical trials. More recently, Dr. Lennon has led efforts to achieve FDA approval for both large-scale genomics projects (as co-Chair of the regulatory working group for NIH’s All of Us Research Project) and for Broad’s own clinical diagnostic for COVID-19 testing process that has delivered >37 million diagnostic test results to people in the New England region.
Dr Lennon received a Ph.D. in Pharmacology from University College Dublin and completed his Postdoctoral studies at Harvard Medical School and Massachusetts General Hospital. He holds an executive certificate in management from the MIT Sloan School of Management. Lennon is also an Adjunct Professor of Biomedical Engineering at Tufts University.